Evaluation of an antibiotic intravenous to oral sequential therapy program

Aim This study was designed to analyse the drug consumption difference and economic impact of an antibiotic sequential therapy focused on quinolones. Method We studied the consumption of quinolones (ofloxacin/levofloxacin and ciprofloxacin) 6 months before and after the implementation of a sequentia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2005-01, Vol.14 (1), p.53-59
Hauptverfasser: Pablos, Ana I., Escobar, Ismael, Albiñana, Sandra, Serrano, Olga, Ferrari, José M., de Tejada, Alberto Herreros
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim This study was designed to analyse the drug consumption difference and economic impact of an antibiotic sequential therapy focused on quinolones. Method We studied the consumption of quinolones (ofloxacin/levofloxacin and ciprofloxacin) 6 months before and after the implementation of a sequential therapy program in hospitalised patients. It was calculated for each antibiotic, in its oral and intravenous forms, in defined daily dose (DDD/100 stays per day) and economical terms (drug acquisition cost). At the beginning of the program ofloxacin was replaced by levofloxacin and, since their clinical uses are similar, the consumption of both drugs was compared during the period. Results In economic terms, the consumption of intravenous quinolones decreased 60% whereas the consumption of oral quinolones increased 66%. In DDD/100 stays per day, intravenous forms consumption decreased 53% and oral forms consumption increased 36%. Conclusions Focusing on quinolones, the implementation of a sequential therapy program based on promoting an early switch from intravenous to oral regimen has proved its capacity to alter the utilisation profile of these antibiotics. The program has permitted the hospital a global saving of $41 420 for these drugs during the period of time considered. Copyright © 2004 John Wiley & Sons, Ltd.
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.1042